ETON at a glance
Eton Pharmaceuticals, Inc. (ETON, SEC CIK 1710340) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Eton Pharmaceuticals, Inc. (ETON) reported revenue of $80.0 million (up 104.9% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.17.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Eton Pharmaceuticals, Inc. (ETON) shares worth $330.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by CASAMENTO CHARLES J on November 10, 2026 of 2,903 shares at $67.87 per share.
- In the last 90 days, ETON insiders reported 0 open-market purchases ($0) and 12 open-market sales ($10.4M) on Form 4, a net sale of $10.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $80.0M
- +104.9% vs prior year
- Insiders · 90 days
- 0 buys · 12 sells
- Net −$10.4M
- 13F holders
- 27 funds
- $330.8M · +3 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes identified from the 2025 10-K risk factors
- Carried-forward business risk: Unanticipated risks may materially affect operations and financial condition
- Carried-forward regulatory risk: Additional unknown risks may materially harm future results
Management Discussion & Analysis
- Quarterly revenue $57,925, up $35,466 YoY from $22,459, driven by HEMANGEOL® acquisition and higher product sales
- Gross margin 76.5% vs 35.0% YoY, gross profit $44,301 vs $7,855
- Strongest products: ALKINDI SPRINKLE®, KHINDIVI™, INCRELEX® U.S., GALZIN®, DESMODA™, Carglumic Acid; weakest, INCRELEX® outside U.S.
- Cash $55.6M, operating cash flow $49,901, investing use $18,308 including $14,100 HEMANGEOL® rights payment
- Near-term headwinds: higher G&A, FDA fees after orphan drug exemption loss, and increased R&D investment in ASN-001 and glyburide oral suspension
AI summary of the ETON 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $57.9M, up 158% YoY, driven by HEMANGEOL and broad portfolio growth
- Adjusted EBITDA $28.5M, or 49% margin, versus 13% prior year, signaling substantial operating leverage
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026
- Press release attached as Exhibit 99.1, containing the underlying financial results
Item 8.01: Other Events
- ET-700 showed better tolerability: treatment-related adverse events in 1 of 12 participants versus 8 of 12 for GALZIN
- Copper absorption inhibition was weaker: hepatic copper uptake decreased 12% with ET-700 versus 46% with GALZIN
Item EX-99.1: Item EX-99.1
- Preliminary ET-700 study showed treatment-related adverse events in 1 of 12 participants, versus 8 of 12 for GALZIN
- Gastrointestinal event rate 0.30 per 100 participant-days for ET-700, versus 5.35 for GALZIN and 0.89 for placebo
Item 8.01: Other Events
- ET-900 expands Eton’s pipeline into infantile and refractory epileptic spasms using mecasermin injection
- Baylor College of Medicine license secures patent rights for IGF-1 use in spasms
Item EX-99.1: Item EX-99.1
- ET-900 expands INCRELEX’s potential indications into infantile and epileptic spasms through licensed Baylor College of Medicine patent rights
- FDA IND submitted for investigator-sponsored Phase 2 study, with first dosing targeted for Q1 2027
AI summaries of ETON 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ETON
Don't miss the next ETON filing
- Alerts as it files. A push when ETON files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ETON, by share count.
- Ask anything. An AI agent that reads every ETON filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| CASAMENTO CHARLES J | Sell | Nov 10, 2026 | 2,903 | $67.87 |
| CASAMENTO CHARLES J | Sell | Nov 10, 2026 | 14,715 | $65.32 |
| CASAMENTO CHARLES J | Sell | Nov 10, 2026 | 33,956 | $67.11 |
| CASAMENTO CHARLES J | M | Nov 10, 2026 | 27,400 | $3.58 |
| CASAMENTO CHARLES J | M | Nov 10, 2026 | 21,000 | $3.78 |
| CASAMENTO CHARLES J | Sell | Nov 10, 2026 | 6,380 | $64.33 |
| CASAMENTO CHARLES J | M | Nov 10, 2026 | 19,655 | $8.61 |
| CASAMENTO CHARLES J | Sell | Nov 10, 2026 | 22,601 | $66.26 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $39.0M | $80.0M |
| Gross Profit | - | $23.4M | $42.7M |
| Operating Income | - | -$2.6M | -$844K |
| Net Income | - | -$3.8M | -$4.6M |
| Gross Margin | - | 60.0% | 53.5% |
| Op. Margin | - | -6.7% | -1.1% |
| Net Margin | - | -9.8% | -5.8% |
| Balance Sheet | |||
| Total Assets | $31.7M | $76.1M | $92.1M |
| Equity | $15.5M | $24.4M | $26.2M |
| ROE | - | -15.7% | -17.6% |
| Per Share | |||
| EPS | - | $-0.15 | $-0.17 |
| Cash Flow | |||
| Operating CF | - | $969K | $10.5M |
| CapEx | - | $26K | $333K |
Source: XBRL data in Eton Pharmaceuticals, Inc. (ETON)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ETON share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $330.8M |
| Q2 2026 | 24 | $219.2M |
| Q1 2026 | 22 | $128.3M |
| Q4 2025 | 22 | $92.5M |
| Q3 2025 | 20 | $134.5M |
| Q2 2025 | 18 | $74.9M |
| Q1 2025 | 15 | $34.6M |
| Q4 2024 | 10 | $24.4M |
- Vanguard Capital Management LLC+226.8K (+23%)
- BlackRock+200.1K (+11%)
- Dimensional Fund Advisors+170.4K (+401%)
- Goldman Sachs Group+130.2K (+98%)
- Invesco Ltd+89.1K (+267%)
- Morgan Stanley−254.8K (-33%)
- JPMorgan Chase & Co−155.7K (-81%)
- D.E. Shaw & Co−117.5K (-62%)
- Bank of America Corp−86.8K (-61%)
- Two Sigma Investments−80.9K (-70%)
- FMR LLC (Fidelity)−2.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ETON filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ETON SEC filings: frequently asked questions
Are ETON insiders buying or selling?
In the last 90 days, Eton Pharmaceuticals, Inc. (ETON) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $10.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ETON stock?
As of September 30, 2026, the largest Eton Pharmaceuticals, Inc. (ETON) holders among the 13F filers tracked by SignalX were BlackRock ($107.9 million), Vanguard Capital Management LLC ($62.0 million), State Street Corp ($39.9 million), Morgan Stanley ($26.4 million), Vanguard Portfolio Management LLC ($13.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ETON's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Eton Pharmaceuticals, Inc. (ETON) reported revenue of $80.0 million (up 104.9% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.17. The figures come from the XBRL data in the 10-K.
What did ETON report in its latest 8-K?
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $57.9M, up 158% YoY, driven by HEMANGEOL and broad portfolio growth.
What are the latest ETON SEC filings?
Eton Pharmaceuticals, Inc. (ETON) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 12, 2026.
What is ETON's SEC CIK number?
Eton Pharmaceuticals, Inc. (ETON)'s SEC Central Index Key (CIK) is 1710340. EDGAR lists every ETON filing under that number.
Ask anything about ETON
The research agent reads ETON's filings, financials, insider trades and 13F holders, then answers with sources.